To understand the molecular basis for hemophilia B in patients with little or no circulating Factor IX antigen, a patient who had less than 0.2% circulating Factor IX antigen (Factor IXSeattle 2) was selected for analysis of his Factor IX gene. Genomic DNA fragments from the abnormal gene were cloned into bacteriophage lambda vectors and recombinant phage were identified using radiolabeled genomic probes obtained from the normal Factor IX gene. The exons and flanking regions of the abnormal gene were sequenced by the dideoxy chain-termination method and this sequence was compared with that of the normal gene. Only one significant difference was observed, the deletion of a single adenine nucleotide in exon V. This resulted in a frameshift that converted an aspartic acid at position 85 in the protein to a valine and the formation of a stop signal at position 86. These data indicate that the gene for Factor IXSeattle 2 codes for an 85 residue polypeptide that terminates after the first epidermal growth factor domain. Thus, the putative Factor IXSeattle 2 polypeptide lacks the second epidermal growth factor domain, the activation peptide, and the catalytic domain present in the normal protein. This provides an explanation for the coagulation disorder in this patient and represents the first report of a single nucleotide deletion and frameshift resulting in hemophilia B.
Introduction
Hemophilia B (Christmas disease) is a bleeding disorder that results from a deficiency of Factor IX coagulant activity. Factor IX is one of several vitamin K-dependent proteins that are converted to serine proteases during coagulation process (1) . Patients with hemophilia B can be grouped into three general categories based upon the amount ofimmunologically reactive Factor IX (cross-reactive material [CRM]') circulating in their blood (2) . Individuals with normal levels of Factor IX antigen, This article was presented in part at the plenary session of the 28th annual meeting of the American Society of Hemotology, San Francisco, CA, and published as an abstract (1986. Blood. 68[Suppl. 1]:340).
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1. Abbreviation used in this paper: CRM, cross-reactive material.
but reduced Factor IX activity are designated CRM+, whereas those with decreased levels of antigen and a corresponding decrease in activity are designated CRMr. Individuals with little or no factor IX antigen circulating in their blood are designated CRM-.
Recently, the molecular basis for hemophilia B has been determined for several CRM+ patients. As anticipated, an amino acid substitution in a critical region of Factor IX, such as the activation site (3) in one CRM' pedigree, is sufficient for decreased Factor IX activity. Three unrelated pedigrees have amino acid substitutions in the leader sequence (4) (5) (6) . Two of the reports suggest a role for the leader sequence in directing the y-carboxylation of the amino-terminal glutamic acid residues (4, 5) . An amino acid substitution near the first epidermal growth factor domain also appears to be responsible for diminished Factor IX activity in another CRM' patient (7). It is not readily evident, however, how this amino acid substitution disrupts the Factor IX activity.
The molecular basis for hemophilia B has also been determined for some CRM-patients. Defects thus far reported range from single nucleotide substitutions in splice junctions (8, 9) to deletions of large segments of the gene (10) (11) (12) . An association between large deletions ofthe gene and production of antibodies directed against Factor IX has been noted by some investigators (10, 11), but not by others (12) .
Cloning of the complementary DNA (cDNA) (13) (14) (15) and gene (16) (17) (18) (21) . The blot was probed with a nick-translated cDNA coding for Factor IX, labeled according to the method of Rigby et al. (22) . Prehybridization was carried out in 50 mM Tris buffer, pH 7.0, containing 0.3 M NaCl and 100 ,g/ml salmon testes DNA (TS buffer) and 50% deionized formamide at 420C for 5 h. Hybridization was performed in a fresh solution of TS buffer with 50% deionized formamide and 1 X 106 cpm/ml radiolabeled Factor IX cDNA. After -24 h, the blot was washed at a final stringency of 0.1 X standard saline citrate (SSC),2 and 0.5% sodium dodecyl sulfate (SDS) at room temperature for 15 min. Excess wash solution was blotted from the nitrocellulose, and the blot was then enclosed in Saran Wrap. The blot was exposed to XRP1 x-ray film with an intensifying screen at -70'C for 4 d.
Construction ofgenomic libraries.
Approximately 100 Mg of DNA from the patient was digested to completion with the restriction endonuclease EcoRI. The restriction fragments were separated according to size on a 0.5% agarose gel in 90 mM Tris buffer, pH 8.3, containing 90 mM boric acid and 2 mM EDTA. Gel slices containing fragments in the range of 10-15, 6.7-9.4, 5.3-7, 3.9-5, and 1.4-2 kilobase (kb) were isolated from the gel and treated, as previously described by Yoshitake et al. (16) .
A separate library was constructed for each size-fractionated fragment. The mixture containing the 12.5-kb fragment coding for exon I was cloned into bacteriophage XEMBL3 (23), as described by Yoshitake et al. (16) . The mixture containing the 4.9-kb fragment coding for exons II, III, and IV and the 4.8-kb fragment coding for exon V was cloned into bacteriophage Xgtl 1 (24) . Likewise, the mixture containing the 1.8-kb fiagment coding for the 3' end ofexon VIII was cloned into Xgtl 1. The mixtures containing the 6.8-kb fragment coding for exon VI and the 5.5-kb fragment coding for exons VII and VIII were cloned into XgtWES (25) SDS, 1 mM EDTA, pH 7.5, at 60'C until the nitrocellulose filters were thoroughly wet (from 15 min to 2 h). Hybridization was carried out in fresh solution containing 2 X 101 cpm/ml probe for 16-24 h. The filters were rinsed in 2X SSC, 0.5% SDS, pH 7.5, at room temperature, followed by a wash in fresh solution at 60'C for 10 min. The filters were dried, covered with Saran Wrap, and exposed to Kodak XAR film in the presence of an intensifying screen at -70'C for 5-20 h. Positive clones were plaque-purified and then amplified by the liquid culture lysis method of Silhavy et al. (28) .
DNA sequencing. Restriction fragments containing exons with some flanking intron sequences were subcloned into Ml 3 phage vectors (29, 30). Sequencing was carried out by the dideoxy chain-termination method of Sanger et al. (31) , as modified for [3"S]dATP (32) .
Oligonucleotide primers specific for Factor IX were designed and used in sequencing several of the exons.
Results and Discussion
A Southern blot of an EcoRI restriction digest of genomic DNA from a patient with severe Factor IX deficiency (Factor IXSea5e 2) was probed with a radiolabeled cDNA for Factor IX.
Four bands of -12.5, 6.8, 5.5, and 4.8 kb were identified by Southern blotting and were indistinguishable from bands present in adjacent lanes from the normal controls. The origin of these bands is illustrated by the EcoRI restriction map shown in Fig. 1 . Note that the 4.8-kb fragment coding for exon V cannot be distinguished from the 4.9-kb band coding for exons II, III, and IV by Southern blot analysis of a 0.7% agarose gel. These preliminary experiments indicated that essentially all of the coding regions for the normal Factor IX gene were also present in the gene from the patient with Factor IX deficiency.
A number of X phage libraries were then constructed from the genomic DNA from the patient, as described under Methods. The number of phage screened for all library constructions is shown in Table I consequences have also been reported for other proteins, such as albumin (37) . The mechanism responsible for the nucleotide deletion in this case is not known. The deleted adenine nucleotide occurs in the first base of the seven-base tandem repeat of ATG-TAAC. There is no similarity of this sequence pattern with patterns previously associated with deletions in the DNA slippage hypothesis (38, 39) or other hypotheses (40, 41) . Instead the deletion may be explained by a mechanism like dislocation mutagenesis, which is not dependent on a specific DNA sequence (42, 43) . As more frameshift mutations are analyzed, it is anticipated that the mechanisms responsible for small deletions will be better understood.
The second difference between the normal and abnormal genes identified a potential FolI restriction fragment length polymorphism at position 6, 843 in which the G in the normal gene has been replaced with an A in the gene for Factor 1XSeatete 2. This eliminates the FokI restriction site that begins at nucleotide number 6,842. Individuals possessing this FokI site would have two fragments of -270 and 1,690 base pairs after digestion with FokI, whereas individuals without the site would have a single fragment of 1,960 base pairs. Since FokI cuts the gene for Factor IX frequently and only 21 bases of the cDNA would hybridize in the area of interest, genomic probes specific for this region would be better suited than cDNA probes when screening for this polymorphism. Alternatively, synthetic oligonucleotide probes designed to match the polymorphic site could be used for screening. The frequency ofthis polymorphism in the population is not currently known. Like other restriction fragment length polymorphisms, its usefulness may be limited because of linkage disequilibrium with other polymorphic sites already identified. This difference occurs within an intron about 1 kb downstream from the third exon and has no effect on the coding region of the gene.
The last three differences between the normal and abnormal genes were found to be errors in the sequence in the 5' flanking region of the normal gene, which was published earlier from our laboratory (16) . These included the replacements of a T with an A at -2,176, -2,104, and -2,105. These errors occur over 2 kb upstream from the promoter region and have no effect on the amino acid sequence of the protein.
A comparison of the tentative structure of the normal circulating Factor IX protein with the structure predicted by the gene for Factor IXs= c2 is shown in Fig. 4 
